Regions included New England (NE), Mid-Atlantic (MA), East North

Regions included New England (NE), Mid-Atlantic (MA), East North Central (ENC), West North Central (WNC), South Atlantic (SA), East South Central (ESC), West South Central (WSC), Mountain (M), and Pacific (P). Results: A total of 2,974 specimens were submitted from 44 states representing all 9 U.S. geographic regions. Median age was 44 years (range, 0.02 to 91) with 59.3% of specimens from males. Despite a significant selleckchem decline in assay success between 2007 and 2012 (81.0% vs. 59.7%, P <0.0001), 1,933 of 2,974 (65.0%) specimens yielded HBV sequences: GT A (37.0%), B (19.2%), C (21.2%), D (12.5%), E (5.1%), F (1.1%), G (2.9%), and H (0.6%), with 7 unresolved sequences (0.4%). GT G (n=56) occurred in males with greater

frequency than GT A, B, C, D, E, F, or H (P <0.01). GT A occurred in males with greater frequency than GT B or GT C (P <0.0001) and occurred more frequently in NE than in ENC, WNC, SA, ESC, or WSC (P <0.015). GT C occurred more frequently in P than in NE,

MA, ENC, WNC, SA or WSC (P <0.05). While no DR was identified in 90.1% of HBV sequences, rates GDC-0068 chemical structure of DR to 1, 2, and 3 drugs were 2.2%, 6.9%, and 0.8%, respectively. Resistance to 3TC and LdT was more frequent in WSC than in NE, ENC, WNC, or SA (P <0.003), while resistance to ETV, 3TC, and LdT was more frequent in P than ENC (P <0.03). Conclusion: Significant differences in HBV GT and DR exist within a large cohort medchemexpress of clinical specimens of U.S. origin and submitted to a national

reference testing laboratory for HBV GT and DR testing. Regional differences may reflect differences in population demographics not considered in these analyses. Disclosures: Joseph D. Yao – Consulting: Abbott Molecular, Inc., Roche Diagnostics Corp.; Grant/Research Support: Abbott Molecular, Inc., Roche Diagnostics Corp. The following people have nothing to disclose: Jeffrey J. Germer, Yuna Choi, Jayawant N. Mandrekar Objective: To compare the viral load decay kinetics of mutant vs. wild-type (WT) virus in chronic hepatitis B infected patients harboring rtM204V and/or rtM204I prior to treatment with TDF or FTC/TDF therapy. Methods: Baseline samples were quantified for rtM204V/I subpopulations from all patients (n=280) in Study GS-US-174-0121, a study that evaluated TDF vs. FTC/TDF in patients harboring LAM-R at screening. Allele-specific PCR assays (AS-PCR) were designed to detect rtM204V or rtM204I mutant and rtM204M WT populations in serum samples with HBV DNA ≥1000 copies/mL, with an assay sensitivity of 0.5% of the total population. Seventeen patients (TDF, n=8; FTC/TDF, n=9) with a mixture of WT and rtM204V/I populations at baseline were evaluated for the percentage of rtM204V/I subpopulations at all study visits until HBV DNA was <1,000 copies/mL. Differences in HBV DNA decline rates and the percentage of rtM204V/I subpopulations on treatment were evaluated using the Wilcoxon Rank Sum and signed rank tests.

Related posts:

1. The source of throughflow water further north due to the closure
2. 5 The subjects included in the study were aged 15 to 54 years and
3. 2008) Accordingly, we cannot tell if the brain regions depicted
4. Sensitivity experiments were integrated for 1000 years A differe
5. Irinotecan less common mutations included 13 cases of various P loop mutations and 5 cases of M351T